Beta Drugs Q2 FY27 Monitoring Agency Report Shows Zero Deviations in Preferential Issue Utilization
Beta Drugs Ltd · Others (Uncategorized) · 12 Nov 2026, 5:06 pm
Beta Drugs Q2 FY27 Monitoring Agency Report Shows Zero Deviations in Preferential Issue Utilization Brickwork Ratings released the Sixth Monitoring Agency Report for Beta Drugs Ltd. for the quarter ended 30th Sep'26, tracking funds raised via a ₹117.02 crore preferential issue of Equity Shares and CCDs (net ₹117.01 crore received). Cumulative utilization stood at ₹47.37 crore with ₹0.00 crore deployed during the quarter, leaving ₹69.64 crore unutilized. The unutilized balance is parked across fixed deposits in HDFC Bank and ICICI Bank yielding 5.50%–6.60%, alongside ₹0.06 crore in the share capital account. No deviations or project implementation delays were reported.
Original exchange filing (PDF)
More announcements from Beta Drugs Ltd
- BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 19-Nov-2026 to consider Other business. · 16 Nov 2026
- To consider other business matters · 16 Nov 2026
- Beta Drugs Limited has informed the Exchange about Transcript · 28 Oct 2026
- Beta Drugs Limited has informed the Exchange about Link of Recording · 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 · 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about Presentation · 22 Oct 2026
- Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about Schedule of meet · 22 Oct 2026
